הרספטין 600 מג5 מל s.c
roche pharmaceuticals (israel) ltd - trastuzumab - תמיסה להזרקה - trastuzumab 600 mg / 5 ml - trastuzumab
פרילידן
halperin n.h. medic ltd, israel - lidocaine; prilocaine - קרם - prilocaine 25 mg / 1 g; lidocaine 25 mg / 1 g - prilocaine
יירבוי 5 מגמל
bristol, myers squibb (israel) limited, israel - ipilimumab - תרכיז להכנת תמיסה לאינפוזיה - ipilimumab 5 mg/ml - ipilimumab - ipilimumab - yervoy (ipilimumab) is indicated for the treatment of unresectable or metastatic melanoma.
סלנייטו 1 מג
neurim pharmaceuticals (1991) ltd, israel - melatonin - טבליות בשחרור ממושך - melatonin 1 mg - melatonin
סלנייטו 5 מג
neurim pharmaceuticals (1991) ltd, israel - melatonin - טבליות בשחרור ממושך - melatonin 5 mg - melatonin
לנטון 30
rafa laboratories ltd - lansoprazole - קפסולות - lansoprazole 30 mg - lansoprazole - lansoprazole - for the treatment of duodenal ulcer, benign gastric ulcer, reflux oesophagitis and acid related disorders of the upper gastrointestinal tract. healing, long- term treatment and maintenance therapy for patients with gastro-oesophageal reflux disease (gerd) or duodenal ulcer. prevention of relapse in patients with gerd or duodenal ulcer. eradication of h. pylori from the upper gastrointestinal tract in patients ,with duodenal ulcer, gastritis or benign ulcer (in combination with appropriate antibiotics). short- term- treatment (up to four weeks) of heartburn and/or upper epigastric pain associated with acid-related dyspepsia. long-term management of pathological hypersecretory conditions including zollinger ellison syndrome. treatment and prophylaxis of nsaid- associated benign gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued nsaid treatment.
לנטון 15
rafa laboratories ltd - lansoprazole - קפסולות - lansoprazole 15 mg - lansoprazole - lansoprazole - for the treatment of duodenal ulcer, benign gastric ulcer, reflux oesophagitis and acid related disorders of the upper gastrointestinal tract. healing, long- term treatment and maintenance therapy for patients with gastro-oesophageal reflux disease (gerd) or duodenal ulcer. prevention of relapse in patients with gerd or duodenal ulcer. eradication of h. pylori from the upper gastrointestinal tract in patients ,with duodenal ulcer, gastritis or benign ulcer (in combination with appropriate antibiotics). short- term- treatment (up to four weeks) of heartburn and/or upper epigastric pain associated with acid-related dyspepsia. long-term management of pathological hypersecretory conditions including zollinger ellison syndrome. treatment and prophylaxis of nsaid- associated benign gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued nsaid treatment.
לנסופרזול טבע 15 מג
teva pharmaceutical industries ltd, israel - lansoprazole - קפסולות - lansoprazole 15 mg - lansoprazole - lansoprazole - for the treatment of duodenal ulcer, benign gastric ulcer, reflux oesophagitis and acid related disorders of the upper gastrointestinal tract. healing, long term treatment and maintenance therapy for patients with gastro oesophageal reflux disease (gord) or duodenal ulcer. prevention of relapse in patients with gord or duodenal ulcer. eradication of h. pylori from the upper gastrointestinal tract in patients with duodenal ulcer, gastritis or benign ulcer (in combination with appropriate antibiotics). short term treatment (up to four weeks) of heartburn and/or upper epigastric pain associated with acid-related dyspepsia. long-term management of pathological hypersecretory conditions including zollinger ellison syndrome.treatment and prophylaxis of nsaid- associated benign gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued nsaid treatment.
לנסופרזול טבע 15 מג
teva pharmaceutical industries ltd, israel - lansoprazole - קפסולות - lansoprazole 15 mg - lansoprazole - lansoprazole - for the treatment of duodenal ulcer, benign gastric ulcer, reflux oesophagitis and acid related disorders of the upper gastrointestinal tract. healing, long term treatment and maintenance therapy for patients with gastro oesophageal reflux disease (gord) or duodenal ulcer. prevention of relapse in patients with gord or duodenal ulcer. eradication of h. pylori from the upper gastrointestinal tract in patients with duodenal ulcer, gastritis or benign ulcer (in combination with appropriate antibiotics). short term treatment (up to four weeks) of heartburn and/or upper epigastric pain associated with acid-related dyspepsia. long-term management of pathological hypersecretory conditions including zollinger ellison syndrome.treatment and prophylaxis of nsaid- associated benign gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued nsaid treatment.